CFO SpotlightsCareers of chief financial officers, from the filings. Records as of October 28, 2026
  1. CFO Spotlights
  2. Profiles
  3. Kevin G. Sarney

Profile

Kevin G. Sarney

interim chief financial officer, Atara Biotherapeutics, Inc.

In the seat, on an interim basis. First published here October 28, 2026; built from records as of October 28, 2026.

Kevin G. Sarney has been interim chief financial officer of Atara Biotherapeutics, Inc. since June 26, 2026, according to the company's filing of June 26, 2026.1

The filing gives Kevin G. Sarney's previous role as Life Science Practice Leader at Charles River CFO, Inc.1 Kevin G. Sarney joined from outside Atara Biotherapeutics, Inc., by the record's reading of the filing.1

Seats

The seat in the record

CompanyTitle as filedStandingFilings
Atara Biotherapeutics, Inc. (ATRA)
Biological Products, (No Diagnostic Substances)
interim chief financial officerIn the seat, on an interim basis1

Company names link to the company's page in the record at CFO Tribune, which holds the seat history.

The record

Filing by filing, latest first

  1. June 26, 2026effective

    Atara Biotherapeutics, Inc. named Kevin G. Sarney interim chief financial officer, effective June 26, 2026.

    Sarney, Life Science Practice Leader at Charles River CFO, Inc. (“CRCFO”), as interim chief financial officer, effective as of June 26, 2026.

    [1] Filing by Atara Biotherapeutics, Inc., filed with the SEC on June 26, 2026. Read the filing. The record at CFO Tribune.

Sources

Sources

  1. Current report filed with the SEC, Atara Biotherapeutics, Inc.. U.S. Securities and Exchange Commission, EDGAR, filed June 26, 2026. sec.gov; record.

Corrections and removal

If a line here is wrong, or Kevin G. Sarney wants this profile taken down, write to corrections@cfospotlights.com. Corrections are made on the page with a dated note; removal requests are answered within 72 hours. The underlying filings stay public at the SEC.